If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 261 - 263 of 263
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy Of ADP-A2m4cd8 As Monotherapy or in Combination with Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
Protocol No
ADP-0055-001-MAGE-A4-SURPASS
Categories
Cancer,
Colorectal,
Skin Cancers,
Thoracic Cancers,
Sarcoma,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Other Respiratory,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Ovary,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus
Open-Label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects with Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
Protocol No
CARSGEN-CT041-ST-02
Categories
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma
In this study we want to find out more about an investigational drug, ZN-c3, in people with
recurrent or persistent Uterine Serous Carcinoma (USC)
recurrent or persistent Uterine Serous Carcinoma (USC)
Protocol No
ERGOMED-ZN-C3-004
Categories